{"title":"FDA panel backs new Alzheimer’s drug, despite risks and uncertainties","link":"https://www.science.org/content/article/fda-panel-backs-new-alzheimer-drug-despite-risks-uncertainties","date":1718133600000,"content":"Pivotal trial of Eli Lilly’s donanemab leaves questions about how to prescribe it and minimize side effects","author":"","siteTitle":"Science","siteHash":"08244134beaa7712a45a99601e5e0d25fd23f6384c4a65e503ee732006dc374e","entryHash":"55bb033f74851ce415b0216dca06a34e8b354a4f06e3bfe6ccce3d5ea2aa6367","category":"Interdisciplinary"}